ZÜRICH, SWITZERLAND – EQS Newswire – 26 October 2021 – Xlife Sciences AG has signed a strategic partnership with the development organization Peace City World as part of the Vision 2030 future program. Peace City World is the official developer of four Smart Cities in Saudi Arabia and Tunisia as well as part of Vision 2030. The program was launched by the Saudi Crown Prince in 2016 and aims to reduce Saudi Arabia’s dependence on fossil fuels and diversify its economy financially. As part of the partnership, Xlife Sciences will be granted a budget of up to 50 Million US Dollars. The core focus is the establishment of an innovation center and technology transfer for the Smart Cities initiative.
The partnership of Xlife Sciences AG with Vision 2030 takes place in the field of sustainable health and particularly focuses on promoting innovation and technology transfer to the Middle East. Oliver R. Baumann, CEO of Xlife Sciences sees significant potential in the collaboration: “For Xlife, the partnership with Saudi Arabia is a recognition of our work and a step towards more international presence and innovation in our four pillars of technology platforms, biotech, medtech and artificial intelligence.” “Furthermore, by participating in the program, Xlife is significantly expanding its network of relationships and presence in the region. In terms of the program, further license partners for the various technologies may be found, particularly for the exit of project companies and the acceleration of registration processes”, says Baumann.
According to the management of Xlife, the funds of up to 50 Million US Dollars will especially be used for the construction of an innovation center and the further development of smart city technologies. As part of the Smart City Sustainability initiative, Saudi Arabia aims to operate ten cities sustainably in the mid term. Moreover, the funds are also intended to further advance the scaling process of various Xlife project companies.
About Xlife Sciences AG
Xlife Sciences AG is a Swiss company with focus on investing in promising technologies in the life science industry. Xlife Sciences AG is building the bridge from research and development to healthcare markets by supporting researchers and entrepreneurs in positioning, structuring, developing and implementing their concepts. Together with industrial partners or universities, Xlife Sciences AG leads projects through the proof-of-concept phase after an invention disclosure or start-up. Subsequently, the firm focuses on out-licensing or selling the company, often with a combination of a strategic partnership. Xlife Sciences AG offers its investors direct access to the further development of innovative and future-oriented technologies at a very early stage. For more information, please visit: www.xlifesciences.ch